449 related articles for article (PubMed ID: 19273542)
1. Enzymuria determination in children treated with aminoglycosides drugs.
Mohammadi-Karakani A; Asgharzadeh-Haghighi S; Ghazi-Khansari M; Seyed-Ebrahimi A; Ghasemi A; Jabari E
Hum Exp Toxicol; 2008 Dec; 27(12):879-82. PubMed ID: 19273542
[TBL] [Abstract][Full Text] [Related]
2. Proximal tubule damage in patients treated with gentamicin or amikacin.
Wiland P; Szechciński J
Pol J Pharmacol; 2003; 55(4):631-7. PubMed ID: 14581723
[TBL] [Abstract][Full Text] [Related]
3. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin.
Halacova M; Kotaska K; Kukacka J; Vavrova V; Kuzelova M; Ticha J; Prusa R
J Clin Pharm Ther; 2008 Aug; 33(4):409-17. PubMed ID: 18613859
[TBL] [Abstract][Full Text] [Related]
4. [An early and specific indicator of aminoglycoside nephrotoxicity: isoenzyme B of urinary N-acetyl-beta-D-glucosaminidase (NAG)].
Gibey R; Dupond JL; Peltier H; Iehl-Robert M; Henry JC
Pathol Biol (Paris); 1986 May; 34(5):342-5. PubMed ID: 3534703
[TBL] [Abstract][Full Text] [Related]
5. Measurement of urinary N-acetyl-b-D-glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics.
Etherington C; Bosomworth M; Clifton I; Peckham DG; Conway SP
J Cyst Fibros; 2007 Jan; 6(1):67-73. PubMed ID: 16844430
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of urinary N-acetyl-beta-D-glucosaminidase activity in patients receiving aminoglycoside and cephalosporin drugs.
Naruse T; Hirokawa N; Oike S; Maekawa T
Res Commun Chem Pathol Pharmacol; 1981 Feb; 31(2):313-29. PubMed ID: 7221185
[TBL] [Abstract][Full Text] [Related]
7. Urinary excretion rates of multiple renal indicators after kidney transplantation: clinical significance for early graft outcome.
Matteucci E; Carmellini M; Bertoni C; Boldrini E; Mosca F; Giampietro O
Ren Fail; 1998 Mar; 20(2):325-30. PubMed ID: 9574459
[TBL] [Abstract][Full Text] [Related]
8. N-acetyl-beta-D-glucosaminidase enzymuria as an indicator in monitoring the therapy of some rheumatic diseases with potentially nephrotoxic drugs.
Wiland P; Szechiński J
Arch Immunol Ther Exp (Warsz); 1994; 42(4):331-6. PubMed ID: 7487376
[TBL] [Abstract][Full Text] [Related]
9. Mercury in dental restoration: is there a risk of nephrotoxicity?
Mortada WL; Sobh MA; El-Defrawy MM; Farahat SE
J Nephrol; 2002; 15(2):171-6. PubMed ID: 12018634
[TBL] [Abstract][Full Text] [Related]
10. Obstructed versus dilated nonobstructed kidneys in children with congenital ureteropelvic junction narrowing: role of urinary tubular enzymes.
Taha MA; Shokeir AA; Osman HG; Abd El-Aziz Ael-A; Farahat SE
J Urol; 2007 Aug; 178(2):640-6. PubMed ID: 17574624
[TBL] [Abstract][Full Text] [Related]
11. Urinary lipocalin-type prostaglandin D synthase: a potential marker for early gentamicin-induced renal damage?
Nakayama H; Echizen H; Gomi T; Shibuya Y; Nakamura Y; Nakano K; Arashi H; Itai T; Ohnishi S; Tanaka M; Orii T
Ther Drug Monit; 2009 Feb; 31(1):126-30. PubMed ID: 19125150
[TBL] [Abstract][Full Text] [Related]
12. Urinary N-acetyl-beta-D-glucosaminidase (NAG) in aminoglycoside nephrotoxicity.
Assadamongkol K; Tapaneya-Olarn W; Chatasingh S
J Med Assoc Thai; 1989 Jan; 72 Suppl 1():42-6. PubMed ID: 2732646
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of gentamicin, amikacin and dactimicin on excretion of N-acetyl-beta-D-glucosaminidase (NAG) and kidney histological pattern in rats.
Palla R; Paternoster G; Galigani P; Giovannini L; Bertelli AA; Romano MR; Alessandrì MG; Bertelli A
Drugs Exp Clin Res; 1987; 13(12):751-6. PubMed ID: 3447879
[TBL] [Abstract][Full Text] [Related]
14. Urinary phospholipids excretion in neonates treated with amikacin.
Ibrahim S; Langhendries JP; Bernard A; Tulkens PM
Int J Clin Pharmacol Res; 1994; 14(5-6):149-56. PubMed ID: 7672871
[TBL] [Abstract][Full Text] [Related]
15. [Urinary excretion of N-acetyl-beta-D-glucosaminidase (NAG) and its isoenzyme B as a marker of the nephrotoxicity of gentamicin: re-test from an animal model].
Ali-Miraftab H; Bourbouze R; Bondiou MT; Percheron F
Pathol Biol (Paris); 1988 Mar; 36(3):240-4. PubMed ID: 3283687
[TBL] [Abstract][Full Text] [Related]
16. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis.
Glass S; Plant ND; Spencer DA
J Cyst Fibros; 2005 Dec; 4(4):221-5. PubMed ID: 16239129
[TBL] [Abstract][Full Text] [Related]
17. Urinary biomarkers in assessing the nephrotoxic potential of gentamicin in solitary kidney patients after 7 days of therapy.
Gluhovschi G; Gadalean F; Gluhovschi C; Velciov S; Petrica L; Bob F; Bozdog G; Kaycsa A
Ren Fail; 2014 May; 36(4):534-40. PubMed ID: 24456153
[TBL] [Abstract][Full Text] [Related]
18. Role of urinary tubular enzymes in evaluation of children with ureteropelvic junction narrowing under conservative management.
Shokeir AA; Taha MA
Urology; 2009 May; 73(5):1016-20. PubMed ID: 19394498
[TBL] [Abstract][Full Text] [Related]
19. Enzymuria as a marker of renal injury and disease: studies of N-acetyl-beta-glucosaminidase in the general population and in patients with renal disease.
Kunin CM; Chesney RW; Craig WA; England AC; DeAngelis C
Pediatrics; 1978 Nov; 62(5):751-60. PubMed ID: 364392
[TBL] [Abstract][Full Text] [Related]
20. [Excretion of N-acetyl-beta-D-glucosaminidase in the urine of children with type I juvenile diabetes mellitus and of patients treated with the aminoglycoside amikacin].
Wiesmann U; Peheim E; Colombo JP
Klin Wochenschr; 1989; 67 Suppl 17():40-3. PubMed ID: 2739356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
